OGN - Organon & Co.
Close
14.83
0.020 0.135%
Share volume: 53,151
Last Updated: Thu 26 Dec 2024 08:30:07 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$14.81
0.02
0.14%
Fundamental analysis
58%
Profitability
42%
Dept financing
50%
Liquidity
59%
Performance
76%
Performance
5 Days
0.20%
1 Month
-6.71%
3 Months
-23.16%
6 Months
-28.60%
1 Year
4.25%
2 Year
-47.26%
Key data
Stock price
$14.83
DAY RANGE
$14.62 - $14.90
52 WEEK RANGE
$14.48 - $23.10
52 WEEK CHANGE
$1.73
DIVIDEND
$0.28
EX-DIVIDEND DATE
08/16/2024
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Kevin Ali
Region: US
Website: organon.com
Employees: 10,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: organon.com
Employees: 10,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies.
Recent news